Norethandrolone
Trade name: Pronabol
NORETHANDROLONE, a nandrolone derivative, is a synthetic hormone with anabolic and androgenic properties and moderate progestational activity. It was used to treat, among others, anorexia nervosa, severe burns and trauma, decubitus ulcers, osteoporosis, gastrointestinal diseases. Its list of prescriptions included preparation for and recovery from surgery, bone fracture healing, severe or prolonged illness, and various forms of malnourishment in adults and children. It was withdrawn for the market in most countries in the 1960s, however, it remains viable on the veterinary drug market in Australia. — NCATS
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Earliest trial started Jun 1, 2002 (NCT00700544)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Androgen ReceptorAGONIST
AR agonist
Chemistry & pharmacology
SMILES
CC[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@]12C- Mol. weight
- 302.451 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSP7W01638W6 ↗
- ChEMBLCHEMBL1697845 ↗
Also known as
- nilevar
- norethandrolone
- norethandrolone
- norethandrolone
- norethandrolone
- norethandrolone
- norethandrolone
- norethandrolone
- norethandrolone
- norethandrolone
- pronabol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00700544 | Phase 3 | Jun 1, 2002 | French Innovative Leukemia Organisation, GOELAMS Cooperative Group, University of Grenoble |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| French Innovative Leukemia Organisation | Academic/Hospital | 1 | 0 | 1 | 2002 |
| GOELAMS Cooperative Group | Academic/Hospital | 1 | 0 | 1 | 2002 |
| University of Grenoble | Academic/Hospital | 1 | 1 | 1 | 2002 |